Stock Research for MYGN


Featured Broker: Ally Invest

Get the due diligence for another stock.


MYGN Stock Chart & Research Data

The MYGN chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MYGN chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


MYGN Due diligence Resources & Stock Charts

The MYGN stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MYGN Detailed Price Forecast - CNN Money CNN View MYGN Detailed Summary - Google Finance
Yahoo View MYGN Detailed Summary - Yahoo! Finance Zacks View MYGN Stock Research & Analysis -

Stock Analysis

TradeIdeas View MYGN Trends & Analysis - Trade-Ideas Barrons View MYGN Major Holders - Barrons
NASDAQ View MYGN Call Transcripts - NASDAQ Seeking View MYGN Breaking News & Analysis - Seeking Alpha
Spotlight View MYGN Annual Report - OTC Report View MYGN OTC Short Report -
TradeKing View MYGN Fundamentals - TradeKing Charts View MYGN SEC Filings - Bar Chart
WSJ View Historical Prices for MYGN - The WSJ Morningstar View Performance/Total Return for MYGN - Morningstar
MarketWatch View the Analyst Estimates for MYGN - MarketWatch CNBC View the Earnings History for MYGN - CNBC
StockMarketWatch View the MYGN Earnings - StockMarketWatch MacroAxis View MYGN Buy or Sell Recommendations - MacroAxis
Bullish View the MYGN Bullish Patterns - American Bulls Short Pains View MYGN Short Pain Metrics -

Social Media Mentions

StockTwits View MYGN Stock Mentions - StockTwits PennyStocks View MYGN Stock Mentions - PennyStockTweets
Twitter View MYGN Stock Mentions - Twitter Invest Hub View MYGN Investment Forum News - Investor Hub
Yahoo View MYGN Stock Mentions - Yahoo! Message Board Seeking Alpha View MYGN Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for MYGN - Insider Cow View Insider Transactions for MYGN - Insider Cow
CNBC View MYGN Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MYGN - OTC Markets
Yahoo View Insider Transactions for MYGN - Yahoo! Finance NASDAQ View Institutional Holdings for MYGN - NASDAQ

Stock Charts

FinViz View MYGN Stock Insight & Charts - StockCharts View MYGN Investment Charts -
BarChart View MYGN Stock Overview & Charts - BarChart Trading View View MYGN User Generated Charts - Trading View

Latest Financial News for MYGN

New Studies Highlight Performance of Vectra® Test in Patients with Rheumatoid Arthritis Who Were Treated with Tofacitinib and Rituximab
Posted on Friday October 19, 2018

Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, today announced new data from two studies of Vectra® that evaluated the test’s ability to track treatment response in patients with rheumatoid arthritis (RA).  The studies were conducted by academic collaborators and will be presented at the American College of Rheumatology meeting in Chicago, IL.  The key findings are that Vectra statistically significantly predicted response to tofacitinib and tracked response to rituximab.

See what the IHS Markit Score report has to say about Myriad Genetics Inc.
Posted on Thursday October 18, 2018

Myriad Genetics Inc NASDAQ/NGS:MYGN

Bendcare Endorses Vectra® Testing for Patients with Rheumatoid Arthritis
Posted on Thursday October 18, 2018

Myriad Genetics, Inc. (MYGN), a global leader in personalized medicine, announced today that Bendcare, a large professional organization empowering community rheumatologists in the United States, has endorsed Vectra® testing for adults with rheumatoid arthritis (RA).  Bendcare focuses on the optimization of the patient journey and the specialty medical office through provider and patient education, product acquisition, and world-class products and data solutions, including a revolutionary prospective data analytics platform called Columbus.

Myriad Receives FDA Approval of BRACAnalysis CDx® as Companion Diagnostic for Pfizer’s TALZENNA® (talazoparib)
Posted on Tuesday October 16, 2018

Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved BRACAnalysis CDx® to be used by healthcare professionals to identify patients with HER2-negative metastatic breast cancer (mBC) who have a germline BRCA mutation and are eligible for treatment with Pfizer’s PARP (poly ADP ribose polymerase) inhibitor, TALZENNA® (talazoparib). TALZENNA is indicated for the treatment of adult patients with deleterious or suspected deleterious germline (inherited) BRCA-mutated HER2-negative locally advanced or mBC.  One in eight women are diagnosed with breast cancer in the United States, and one-third will progress to the metastatic stage of the disease.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.